SCHEDULE: RA Capital Amends Protara Therapeutics Stake

RA Capital Management and its affiliates have filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Protara Therapeutics, Inc. as of June 30, 2025.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed Amendment No. 2 to their Schedule 13G regarding their beneficial ownership in Protara Therapeutics, Inc.
• As of June 30, 2025, the Reporting Persons collectively beneficially own 1,971,765 shares of Protara Therapeutics, Inc. Common Stock.
• This represents 4.9% of the class, rounded down from 4.99% due to EDGAR filing system limitations.
• The ownership includes 1,039,295 shares of Common Stock directly held by RA Capital Healthcare Fund, L.P.
• It also includes pre-funded warrants exercisable for up to 1,400,144 shares, subject to beneficial ownership blockers.
• A 4.99% beneficial ownership blocker prevents the exercise of certain pre-funded warrants if it would result in ownership exceeding 1,971,765 shares.
• The 4.99% beneficial ownership percentage is calculated based on 38,581,863 shares outstanding as of May 1, 2025, plus 932,470 shares issuable from pre-funded warrants.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in beneficial ownership below the 5% threshold, suggesting a potential decrease in conviction or a strategic rebalancing by a significant institutional investor. While the investment firm remains a holder, the cap on further warrant exercise also limits potential upside influence.

Positives

• Continued investment by a specialized healthcare fund (RA Capital) indicates ongoing interest in Protara Therapeutics.
• The presence of beneficial ownership blockers suggests a strategic approach to maintaining a specific ownership threshold without triggering certain regulatory requirements.

Negatives

• The reported beneficial ownership of 4.9% (rounded from 4.99%) is below the 5% threshold that typically triggers an initial Schedule 13G filing, implying a reduction in their reported stake from a previous filing, which could be interpreted as a decrease in conviction or a strategic rebalancing.
• The presence of a 4.99% beneficial ownership blocker on a significant portion of their pre-funded warrants limits their ability to increase their stake in Protara Therapeutics beyond this threshold without triggering additional regulatory requirements or potentially renegotiating terms.

Risks

• The beneficial ownership blockers (9.99% and 4.99%) on pre-funded warrants limit the Reporting Persons' ability to fully exercise their warrants and increase their stake, potentially restricting their influence or upside participation in the company's growth.
• The calculation of beneficial ownership is complex due to the inclusion of pre-funded warrants and the application of ownership blockers, which could lead to misinterpretations of the actual economic exposure or voting power.

Future Outlook

NA

Industry Context

This filing reflects a prominent healthcare-focused investment firm's continued, albeit capped, stake in a biotechnology or pharmaceutical company, common in the highly specialized and capital-intensive healthcare sector where strategic investments by institutional funds are crucial.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional investor's reported stake could be perceived negatively, potentially impacting investor confidence and share price. The presence of ownership blockers might also limit the potential for future large-scale investment from this entity.
• Company Management: The filing provides transparency regarding a major investor's position, which management would monitor for strategic implications.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership by a key institutional investor, RA Capital Management, to just under 5%. While this suggests a potential rebalancing or decreased conviction, RA Capital remains a significant shareholder. The presence of beneficial ownership blockers limits their ability to increase their stake further via warrants, which could cap future upside influence. Given this mixed signal, a "hold" recommendation is appropriate, advising investors to maintain their current position while monitoring future developments from both the company and this significant investor.

Keywords

Protara Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Healthcare Investment, Institutional Investor, Equity Stake